{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T03:08:00Z","timestamp":1782270480011,"version":"3.54.5"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T00:00:00Z","timestamp":1528416000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1038\/s41584-018-0025-5","type":"journal-article","created":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T16:26:15Z","timestamp":1528475175000},"page":"488-498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Cannabinoids for the treatment of rheumatic diseases \u2014 where do we stand?"],"prefix":"10.1038","volume":"14","author":[{"given":"Daphna","family":"Katz-Talmor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itay","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bat-Sheva","family":"Porat-Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,8]]},"reference":[{"key":"25_CR1","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1931-0846.2014.12038.x","volume":"104","author":"B Warf","year":"2014","unstructured":"Warf, B. High points: an historical geography of cannabis. Geogr. Rev. 104, 414\u2013438 (2014).","journal-title":"Geogr. Rev."},{"key":"25_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1590\/S1516-44462006000200015","volume":"28","author":"AW Zuardi","year":"2006","unstructured":"Zuardi, A. W. History of cannabis as a medicine: a review. Revista Brasileira Psiquiatria 28, 153\u2013157 (2006).","journal-title":"Revista Brasileira Psiquiatria"},{"key":"25_CR3","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1038\/525S10a","volume":"525","author":"S Pain","year":"2015","unstructured":"Pain, S. A potted history. Nature 525, S10\u2013S11 (2015).","journal-title":"Nature"},{"key":"25_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.autrev.2016.02.008","volume":"15","author":"V Katchan","year":"2016","unstructured":"Katchan, V., David, P. & Shoenfeld, Y. Cannabinoids and autoimmune diseases: a systematic review. Autoimmun. Rev. 15, 513\u2013528 (2016).","journal-title":"Autoimmun. Rev."},{"key":"25_CR5","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1021\/ja01062a046","volume":"86","author":"Y Gaoni","year":"1964","unstructured":"Gaoni, Y. & Mechoulam, R. Isolation, structure, and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86, 1646\u20131647 (1964).","journal-title":"J. Am. Chem. Soc."},{"key":"25_CR6","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0026-895X(25)09876-1","volume":"34","author":"WA Devane","year":"1988","unstructured":"Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S. & Howlett, A. C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34, 605\u2013613 (1988).","journal-title":"Mol. Pharmacol."},{"key":"25_CR7","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1126\/science.1470919","volume":"258","author":"WA Devane","year":"1992","unstructured":"Devane, W. A. et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946\u20131949 (1992).","journal-title":"Science"},{"key":"25_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0006-2952(95)00109-D","volume":"50","author":"R Mechoulam","year":"1995","unstructured":"Mechoulam, R. et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83\u201390 (1995).","journal-title":"Biochem. Pharmacol."},{"key":"25_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.tips.2015.02.008","volume":"36","author":"M Maccarrone","year":"2015","unstructured":"Maccarrone, M. et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol. Sci. 36, 277\u2013296 (2015).","journal-title":"Trends Pharmacol. Sci."},{"key":"25_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1515\/jbcpp-2015-0091","volume":"27","author":"R Mechoulam","year":"2016","unstructured":"Mechoulam, R. Cannabis - the Israeli perspective. J. Basic Clin. Physiol. Pharmacol. 27, 181\u2013187 (2016).","journal-title":"J. Basic Clin. Physiol. Pharmacol."},{"key":"25_CR11","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1093\/brain\/awg143","volume":"126","author":"L Iversen","year":"2003","unstructured":"Iversen, L. Cannabis and the brain. Brain 126, 1252\u20131270 (2003).","journal-title":"Brain"},{"issue":"Suppl. 1","key":"25_CR12","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1038\/sj.ijo.0803273","volume":"30","author":"K Mackie","year":"2006","unstructured":"Mackie, K. Mechanisms of CB1 receptor signaling: endocannabinoid modulation of synaptic strength. Int. J. Obes. 30 (Suppl. 1), S19\u2013S23 (2006).","journal-title":"Int. J. Obes."},{"key":"25_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1210\/er.2005-0009","volume":"27","author":"U Pagotto","year":"2006","unstructured":"Pagotto, U., Marsicano, G., Cota, D., Lutz, B. & Pasquali, R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr. Rev. 27, 73\u2013100 (2006).","journal-title":"Endocr. Rev."},{"key":"25_CR14","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2174\/187152709789824660","volume":"8","author":"J Guindon","year":"2009","unstructured":"Guindon, J. & Hohmann, A. G. The endocannabinoid system and pain. CNS Neurol. Disord. Drug Targets 8, 403\u2013421 (2009).","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"25_CR15","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3109\/08830185.2014.921165","volume":"34","author":"JM Sido","year":"2015","unstructured":"Sido, J. M., Nagarkatti, P. S. & Nagarkatti, M. Role of endocannabinoid activation of peripheral CB1 receptors in the regulation of autoimmune disease. Int. Rev. Immunol. 34, 403\u2013414 (2015).","journal-title":"Int. Rev. Immunol."},{"key":"25_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/can.2015.0001","volume":"1","author":"SL Dunn","year":"2016","unstructured":"Dunn, S. L., Wilkinson, J. M., Crawford, A., Bunning, R. A. D. & Le Maitre, C. L. Expression of cannabinoid receptors in human osteoarthritic cartilage: implications for future therapies. Cannabis Cannabinoid Res. 1, 3\u201315 (2016).","journal-title":"Cannabis Cannabinoid Res."},{"key":"25_CR17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neuron.2012.09.020","volume":"76","author":"PE Castillo","year":"2012","unstructured":"Castillo, P. E., Younts, T. J., Ch\u00e1vez, A. E. & Hashimotodani, Y. Endocannabinoid signaling and synaptic function. Neuron 76, 70\u201381 (2012).","journal-title":"Neuron"},{"key":"25_CR18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1124\/pr.54.2.161","volume":"54","author":"AC Howlett","year":"2002","unstructured":"Howlett, A. C. et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54, 161\u2013202 (2002).","journal-title":"Pharmacol. Rev."},{"key":"25_CR19","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.2174\/092986710790980023","volume":"17","author":"AC Howlett","year":"2010","unstructured":"Howlett, A. C., Blume, L. C. & Dalton, G. D. CB1 cannabinoid receptors and their associated proteins. Curr. Med. Chem. 17, 1382\u20131393 (2010).","journal-title":"Curr. Med. Chem."},{"key":"25_CR20","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1124\/pr.110.003004","volume":"62","author":"RG Pertwee","year":"2010","unstructured":"Pertwee, R. G. et al. International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol. Rev. 62, 588\u2013631 (2010).","journal-title":"Pharmacol. Rev."},{"key":"25_CR21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1021\/acs.chemrev.5b00411","volume":"116","author":"M Aghazadeh Tabrizi","year":"2016","unstructured":"Aghazadeh Tabrizi, M., Baraldi, P. G., Borea, P. A. & Varani, K. Medicinal chemistry, pharmacology, and potential therapeutic benefits of cannabinoid CB 2 receptor agonists. Chem. Rev. 116, 519\u2013560 (2016).","journal-title":"Chem. Rev."},{"key":"25_CR22","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1093\/rheumatology\/ket447","volume":"53","author":"H Gui","year":"2014","unstructured":"Gui, H. et al. Expression of cannabinoid receptor 2 and its inhibitory effects on synovial fibroblasts in rheumatoid arthritis. Rheumatology 53, 802\u2013809 (2014).","journal-title":"Rheumatology"},{"key":"25_CR23","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.smim.2014.04.002","volume":"26","author":"AM Malfitano","year":"2014","unstructured":"Malfitano, A. M., Basu, S., Maresz, K., Bifulco, M. & Dittel, B. N. What we know and do not know about the cannabinoid receptor 2 (CB2). Semin. Immunol. 26, 369\u2013379 (2014).","journal-title":"Semin. Immunol."},{"key":"25_CR24","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1111\/j.1460-9568.2006.04684.x","volume":"23","author":"M Beltramo","year":"2006","unstructured":"Beltramo, M. et al. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur. J. Neurosci. 23, 1530\u20131538 (2006).","journal-title":"Eur. J. Neurosci."},{"key":"25_CR25","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/cpt.568","volume":"101","author":"D Katz","year":"2016","unstructured":"Katz, D., Katz, I., Porat-Katz, B. & Shoenfeld, Y. Medical cannabis: another piece in the mosaic of autoimmunity? Clin. Pharmacol. Ther. 101, 230\u2013238 (2016).","journal-title":"Clin. Pharmacol. Ther."},{"key":"25_CR26","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3109\/03009742.2015.1020863","volume":"44","author":"G Bellini","year":"2015","unstructured":"Bellini, G. et al. Association between cannabinoid receptor type 2 Q63R variant and oligo\/polyarticular juvenile idiopathic arthritis. Scand. J. Rheumatol. 44, 284\u2013287 (2015).","journal-title":"Scand. J. Rheumatol."},{"key":"25_CR27","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.bbrc.2007.05.178","volume":"359","author":"A Engler","year":"2007","unstructured":"Engler, A. et al. Expression of transient receptor potential vanilloid 1 (TRPV1) in synovial fibroblasts from patients with osteoarthritis and rheumatoid arthritis. Biochem. Biophys. Res. Commun. 359, 884\u2013888 (2007).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"25_CR28","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/1756-185X.13146","volume":"20","author":"N Barrie","year":"2017","unstructured":"Barrie, N. et al. Endocannabinoids in arthritis: current views and perspective. Int. J. Rheum. Dis. 20, 789\u2013797 (2017).","journal-title":"Int. J. Rheum. Dis."},{"key":"25_CR29","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s13075-015-0743-x","volume":"17","author":"T Lowin","year":"2015","unstructured":"Lowin, T. & Straub, R. H. Cannabinoid-based drugs targeting CB1 and TRPV1, the sympathetic nervous system, and arthritis. Arthritis Res. Ther. 17, 226 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"25_CR30","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/bs.apha.2017.04.004","volume":"80","author":"A Irving","year":"2017","unstructured":"Irving, A. et al. Cannabinoid receptor-related orphan G protein-coupled receptors. Adv. Pharmacol. 80, 223\u2013247 (2017).","journal-title":"Adv. Pharmacol."},{"key":"25_CR31","first-page":"11","volume":"1","author":"D Katz","year":"2016","unstructured":"Katz, D., Katz, I. & Shoenfeld, Y. Cannabis and autoimmunity\u2013the neurologic perspective: a brief review. J. Neurol. Neuromed. 1, 11\u201315 (2016).","journal-title":"J. Neurol. Neuromed."},{"key":"25_CR32","first-page":"129","volume":"74","author":"RG Pertwee","year":"1997","unstructured":"Pertwee, R. G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74, 129\u2013180 (1997).","journal-title":"Pharmacol. Ther."},{"key":"25_CR33","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","volume":"150","author":"A Thomas","year":"2007","unstructured":"Thomas, A. et al. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br. J. Pharmacol. 150, 613\u2013623 (2007).","journal-title":"Br. J. Pharmacol."},{"key":"25_CR34","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1152\/physrev.00002.2016","volume":"96","author":"A Ligresti","year":"2016","unstructured":"Ligresti, A., De Petrocellis, L. & Di Marzo, V. From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology. Physiol. Rev. 96, 1593\u20131659 (2016).","journal-title":"Physiol. Rev."},{"key":"25_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0014-2999(98)00392-6","volume":"353","author":"S Ben-Shabat","year":"1998","unstructured":"Ben-Shabat, S. et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur. J. Pharmacol. 353, 23\u201331 (1998).","journal-title":"Eur. J. Pharmacol."},{"key":"25_CR36","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1111\/j.1476-5381.2011.01238.x","volume":"163","author":"EB Russo","year":"2011","unstructured":"Russo, E. B. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br. J. Pharmacol. 163, 1344\u20131364 (2011).","journal-title":"Br. J. Pharmacol."},{"key":"25_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/bs.apha.2017.03.004","volume":"80","author":"EB Russo","year":"2017","unstructured":"Russo, E. B. & Marcu, J. Cannabis pharmacology: the usual suspects and a few promising leads. Adv. Pharmacol. 80, 67\u2013134 (2017).","journal-title":"Adv. Pharmacol."},{"key":"25_CR38","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.phymed.2014.01.009","volume":"21","author":"C-P Jiang","year":"2014","unstructured":"Jiang, C.-P. et al. Anti-rheumatoid arthritic activity of flavonoids from Daphne genkwa. Phytomedicine 21, 830\u2013837 (2014).","journal-title":"Phytomedicine"},{"key":"25_CR39","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.sapharm.2015.09.002","volume":"12","author":"JR Parmar","year":"2016","unstructured":"Parmar, J. R., Forrest, B. D. & Freeman, R. A. Medical marijuana patient counseling points for health care professionals based on trends in the medical uses, efficacy, and adverse effects of cannabis-based pharmaceutical drugs. Res. Soc. Adm. Pharm. 12, 638\u2013654 (2016).","journal-title":"Res. Soc. Adm. Pharm."},{"key":"25_CR40","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa1610300","volume":"376","author":"AJ Adams","year":"2017","unstructured":"Adams, A. J. et al. \u2018Zombie\u2019 outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York. N. Engl. J. Med. 376, 235\u2013242 (2017).","journal-title":"N. Engl. J. Med."},{"key":"25_CR41","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1503\/cmaj.071178","volume":"178","author":"T Wang","year":"2008","unstructured":"Wang, T., Collet, J.-P., Shapiro, S. & Ware, M. A. Adverse effects of medical cannabinoids: a systematic review. CMAJ 178, 1669\u20131678 (2008).","journal-title":"CMAJ"},{"key":"25_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/15563650.2015.1110590","volume":"54","author":"RJ Tait","year":"2015","unstructured":"Tait, R. J., Caldicott, D., Mountain, D., Hill, S. L. & Lenton, S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin. Toxicol. 54, 1\u201313 (2015).","journal-title":"Clin. Toxicol."},{"key":"25_CR43","unstructured":"National Academies of Sciences, Engineering and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research (The National Academies Press, 2017)."},{"key":"25_CR44","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1001\/jamainternmed.2015.7841","volume":"176","author":"R Auer","year":"2016","unstructured":"Auer, R. et al. Association between lifetime marijuana use and cognitive function in middle age. JAMA Intern. Med. 176, 352 (2016).","journal-title":"JAMA Intern. Med."},{"key":"25_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055821","volume":"8","author":"A Batalla","year":"2013","unstructured":"Batalla, A. et al. Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. PLoS ONE 8, e55821 (2013).","journal-title":"PLoS ONE"},{"key":"25_CR46","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/pcn.12085","volume":"67","author":"M Rocchetti","year":"2013","unstructured":"Rocchetti, M. et al. Is cannabis neurotoxic for the healthy brain? A meta-analytical review of structural brain alterations in non-psychotic users. Psychiatry Clin. Neurosci. 67, 483\u2013492 (2013).","journal-title":"Psychiatry Clin. Neurosci."},{"key":"25_CR47","doi-asserted-by":"publisher","first-page":"E2657","DOI":"10.1073\/pnas.1206820109","volume":"109","author":"MH Meier","year":"2012","unstructured":"Meier, M. H. et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc. Natl Acad. Sci. USA 109, E2657\u2013E2664 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"25_CR48","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMra1402309","volume":"370","author":"ND Volkow","year":"2014","unstructured":"Volkow, N. D., Baler, R. D., Compton, W. M. & Weiss, S. R. B. Adverse health effects of marijuana use. N. Engl. J. Med. 370, 2219\u20132227 (2014).","journal-title":"N. Engl. J. Med."},{"key":"25_CR49","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrn.2016.28","volume":"17","author":"HV Curran","year":"2016","unstructured":"Curran, H. V. et al. Keep off the grass? Cannabis, cognition and addiction. Nat. Rev. Neurosci. 17, 293\u2013306 (2016).","journal-title":"Nat. Rev. Neurosci."},{"key":"25_CR50","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/add.13946","volume":"113","author":"MH Meier","year":"2017","unstructured":"Meier, M. H. et al. Associations between adolescent cannabis use and neuropsychological decline: a longitudinal co-twin control study. Addiction 113, 257\u2013265 (2017).","journal-title":"Addiction"},{"key":"25_CR51","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1037\/1064-1297.2.3.244","volume":"2","author":"JC Anthony","year":"1994","unstructured":"Anthony, J. C., Warner, L.a. & Kessler, R. C. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Exp. Clin. Psychopharmacol. 2, 244\u2013268 (1994).","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"25_CR52","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1360-0443.2009.02504.x","volume":"104","author":"A Agrawal","year":"2009","unstructured":"Agrawal, A. & Lynskey, M. T. Candidate genes for cannabis use disorders: findings, challenges and directions. Addiction 104, 518\u2013532 (2009).","journal-title":"Addiction"},{"key":"25_CR53","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1360-0443.2009.02831.x","volume":"105","author":"KJH Verweij","year":"2010","unstructured":"Verweij, K. J. H. et al. Genetic and environmental influences on cannabis use initiation and problematic use: a meta-analysis of twin studies. Addiction 105, 417\u2013430 (2010).","journal-title":"Addiction"},{"key":"25_CR54","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ntt.2016.05.010","volume":"58","author":"AM Smith","year":"2016","unstructured":"Smith, A. M. et al. Prenatal marijuana exposure impacts executive functioning into young adulthood: an fMRI study. Neurotoxicol. Teratol. 58, 53\u201359 (2016).","journal-title":"Neurotoxicol. Teratol."},{"key":"25_CR55","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1056\/NEJMoa1604221","volume":"375","author":"A Kerbrat","year":"2016","unstructured":"Kerbrat, A. et al. Acute neurologic disorder from an inhibitor of fatty acid amide hydrolase. N. Engl. J. Med. 375, 1717\u20131725 (2016).","journal-title":"N. Engl. J. Med."},{"key":"25_CR56","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3109\/00952990.2011.643997","volume":"38","author":"WT Lindsey","year":"2012","unstructured":"Lindsey, W. T., Stewart, D. & Childress, D. Drug interactions between common illicit drugs and prescription therapies. Am. J. Drug Alcohol Abuse 38, 334\u2013343 (2012).","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"25_CR57","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/03602532.2013.849268","volume":"46","author":"SM Stout","year":"2014","unstructured":"Stout, S. M. & Cimino, N. M. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab. Rev. 46, 86\u201395 (2014).","journal-title":"Drug Metab. Rev."},{"key":"25_CR58","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s40262-016-0400-9","volume":"55","author":"GD Anderson","year":"2016","unstructured":"Anderson, G. D. & Chan, L. N. Pharmacokinetic drug interactions with tobacco, cannabinoids and smoking cessation products. Clin. Pharmacokinet. 55, 1353\u20131368 (2016).","journal-title":"Clin. Pharmacokinet."},{"key":"25_CR59","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/epi.13060","volume":"56","author":"AL Geffrey","year":"2015","unstructured":"Geffrey, A. L., Pollack, S. F., Bruno, P. L. & Thiele, E. A. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia 56, 1246\u20131251 (2015).","journal-title":"Epilepsia"},{"key":"25_CR60","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/clpt.2011.188","volume":"90","author":"DI Abrams","year":"2011","unstructured":"Abrams, D. I., Couey, P., Shade, S. B., Kelly, M. E. & Benowitz, N. L. Cannabinoid\u2013opioid interaction in chronic pain. Clin. Pharmacol. Ther. 90, 844\u2013851 (2011).","journal-title":"Clin. Pharmacol. Ther."},{"key":"25_CR61","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1373\/clinchem.2015.238287","volume":"61","author":"RL Hartman","year":"2015","unstructured":"Hartman, R. L. et al. Controlled cannabis vaporizer administration: blood and plasma cannabinoids with and without alcohol. Clin. Chem. 61, 850\u2013869 (2015).","journal-title":"Clin. Chem."},{"key":"25_CR62","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/clc.4960250310","volume":"25","author":"AL McLeod","year":"2002","unstructured":"McLeod, A. L., McKenna, C. J. & Northridge, D. B. Myocardial infarction following the combined recreational use of Viagra and cannabis. Clin. Cardiol. 25, 133\u2013134 (2002).","journal-title":"Clin. Cardiol."},{"key":"25_CR63","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1345\/aph.1M064","volume":"43","author":"W Yamreudeewong","year":"2009","unstructured":"Yamreudeewong, W., Wong, H. K., Brausch, L. M. & Pulley, K. R. Probable interaction between warfarin and marijuana smoking. Ann. Pharmacother. 43, 1347\u20131353 (2009).","journal-title":"Ann. Pharmacother."},{"key":"25_CR64","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/nrrheum.2010.86","volume":"6","author":"Y Shapira","year":"2010","unstructured":"Shapira, Y., Agmon-Levin, N. & Shoenfeld, Y. Geoepidemiology of autoimmune rheumatic diseases. Nat. Rev. Rheumatol. 6, 468\u2013476 (2010).","journal-title":"Nat. Rev. Rheumatol."},{"key":"25_CR65","doi-asserted-by":"publisher","first-page":"R43","DOI":"10.1186\/ar2401","volume":"10","author":"D Richardson","year":"2008","unstructured":"Richardson, D. et al. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res. Ther. 10, R43 (2008).","journal-title":"Arthritis Res. Ther."},{"key":"25_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12950-016-0114-7","volume":"13","author":"T Lowin","year":"2016","unstructured":"Lowin, T., Pongratz, G. & Straub, R. H. The synthetic cannabinoid WIN55,212-2 mesylate decreases the production of inflammatory mediators in rheumatoid arthritis synovial fibroblasts by activating CB2, TRPV1, TRPA1 and yet unidentified receptor targets. J. Inflamm. 13, 15 (2016).","journal-title":"J. Inflamm."},{"key":"25_CR67","doi-asserted-by":"publisher","first-page":"9561","DOI":"10.1073\/pnas.160105897","volume":"97","author":"AM Malfait","year":"2000","unstructured":"Malfait, A. M. et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl Acad. Sci. USA 97, 9561\u20139566 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"25_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-15-275","volume":"15","author":"S Fukuda","year":"2014","unstructured":"Fukuda, S. et al. Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis. BMC Musculoskelet. Disord. 15, 275 (2014).","journal-title":"BMC Musculoskelet. Disord."},{"key":"25_CR69","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.imbio.2014.12.012","volume":"220","author":"H Gui","year":"2015","unstructured":"Gui, H., Liu, X., Liu, L.-R., Su, D.-F. & Dai, S.-M. Activation of cannabinoid receptor 2 attenuates synovitis and joint distruction in collagen-induced arthritis. Immunobiology 220, 817\u2013822 (2015).","journal-title":"Immunobiology"},{"key":"25_CR70","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/rheumatology\/kei183","volume":"45","author":"DR Blake","year":"2006","unstructured":"Blake, D. R., Robson, P., Ho, M., Jubb, R. W. & McCabe, C. S. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 45, 50\u201352 (2006).","journal-title":"Rheumatol"},{"key":"25_CR71","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.3892\/mmr.2016.5137","volume":"13","author":"Y Kong","year":"2016","unstructured":"Kong, Y. et al. Cannabinoid WIN-55,212\u20132 mesylate inhibits ADAMTS-4 activity in human osteoarthritic articular chondrocytes by inhibiting expression of syndecan-1. Mol. Med. Rep. 13, 4569\u20134576 (2016).","journal-title":"Mol. Med. Rep."},{"key":"25_CR72","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1097\/j.pain.0000000000000706","volume":"157","author":"PA Ste-Marie","year":"2016","unstructured":"Ste-Marie, P. A. et al. Survey of herbal cannabis (marijuana) use in rheumatology clinic attenders with a rheumatologist confirmed diagnosis. Pain 157, 2792\u20132797 (2016).","journal-title":"Pain"},{"key":"25_CR73","doi-asserted-by":"publisher","first-page":"46","DOI":"10.7326\/M14-1231","volume":"162","author":"RR Bannuru","year":"2015","unstructured":"Bannuru, R. R. et al. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis. Ann. Intern. Med. 162, 46 (2015).","journal-title":"Ann. Intern. Med."},{"key":"25_CR74","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.joca.2015.04.020","volume":"23","author":"A Sophocleous","year":"2015","unstructured":"Sophocleous, A., B\u00f6rjesson, A. E., Salter, D. M. & Ralston, S. H. The type 2 cannabinoid receptor regulates susceptibility to osteoarthritis in mice. Osteoarthritis Cartilage 23, 1586\u20131594 (2015).","journal-title":"Osteoarthritis Cartilage"},{"key":"25_CR75","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.bcp.2004.11.018","volume":"69","author":"EC Mbvundula","year":"2005","unstructured":"Mbvundula, E. C., Bunning, R. A. D. & Rainsford, K. D. Effects of cannabinoids on nitric oxide production by chondrocytes and proteoglycan degradation in cartilage. Biochem. Pharmacol. 69, 635\u2013640 (2005).","journal-title":"Biochem. Pharmacol."},{"key":"25_CR76","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jor.22660","volume":"32","author":"R G\u00f5mez","year":"2014","unstructured":"G\u00f5mez, R. et al. Endogenous cannabinoid anandamide impairs cell growth and induces apoptosis in chondrocytes. J. Orthop. Res. 32, 1137\u20131146 (2014).","journal-title":"J. Orthop. Res."},{"key":"25_CR77","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/j.pain.2012.04.020","volume":"153","author":"JP Huggins","year":"2012","unstructured":"Huggins, J. P., Smart, T. S., Langman, S., Taylor, L. & Young, T. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 153, 1837\u20131846 (2012).","journal-title":"Pain"},{"key":"25_CR78","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1097\/j.pain.0000000000000260","volume":"156","author":"C Porta La","year":"2015","unstructured":"La Porta, C. et al. Role of the endocannabinoid system in the emotional manifestations of osteoarthritis pain. Pain 156, 2001\u20132012 (2015).","journal-title":"Pain"},{"key":"25_CR79","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.pain.2010.11.025","volume":"152","author":"N Schuelert","year":"2011","unstructured":"Schuelert, N. et al. Local application of the endocannabinoid hydrolysis inhibitor URB597 reduces nociception in spontaneous and chemically induced models of osteoarthritis. Pain 152, 975\u2013981 (2011).","journal-title":"Pain"},{"key":"25_CR80","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.autrev.2017.07.018","volume":"16","author":"D Rossi","year":"2017","unstructured":"Rossi, D. et al. How I treat patients with systemic sclerosis in clinical practice. Autoimmun. Rev. 16, 1024\u20131028 (2017).","journal-title":"Autoimmun. Rev."},{"key":"25_CR81","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1002\/art.27642","volume":"62","author":"S Marquart","year":"2010","unstructured":"Marquart, S. et al. Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. Arthritis Rheum. 62, 3467\u20133476 (2010).","journal-title":"Arthritis Rheum."},{"key":"25_CR82","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/art.24395","volume":"60","author":"A Akhmetshina","year":"2009","unstructured":"Akhmetshina, A. et al. The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum. 60, 1129\u20131136 (2009).","journal-title":"Arthritis Rheum."},{"key":"25_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/srep21703","volume":"6","author":"C R\u00edo del","year":"2016","unstructured":"del R\u00edo, C. et al. The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-\u03b3 and CB2 pathways. Sci. Rep. 6, 21703 (2016).","journal-title":"Sci. Rep."},{"key":"25_CR84","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2353\/ajpath.2010.090763","volume":"177","author":"A Servettaz","year":"2010","unstructured":"Servettaz, A. et al. Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis. Am. J. Pathol. 177, 187\u2013196 (2010).","journal-title":"Am. J. Pathol."},{"key":"25_CR85","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejphar.2016.06.006","volume":"786","author":"L-L Wang","year":"2016","unstructured":"Wang, L.-L. et al. Pharmacological activation of cannabinoid 2 receptor attenuates inflammation, fibrogenesis, and promotes re-epithelialization during skin wound healing. Eur. J. Pharmacol. 786, 128\u2013136 (2016).","journal-title":"Eur. J. Pharmacol."},{"key":"25_CR86","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.3892\/mmr.2016.4961","volume":"13","author":"S Li","year":"2016","unstructured":"Li, S. et al. Cannabinoid CB2 receptors are involved in the regulation of fibrogenesis during skin wound repair in mice. Mol. Med. Rep. 13, 3441\u20133450 (2016).","journal-title":"Mol. Med. Rep."},{"key":"25_CR87","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/rheumatology\/kep189","volume":"48","author":"E Garcia-Gonzalez","year":"2009","unstructured":"Garcia-Gonzalez, E. et al. Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts. Rheumatology 48, 1050\u20131056 (2009).","journal-title":"Rheumatology"},{"key":"25_CR88","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.semarthrit.2016.08.012","volume":"46","author":"F Wolfe","year":"2016","unstructured":"Wolfe, F. et al. 2016 Revisions to the 2010\/2011 fibromyalgia diagnostic criteria. Semin. Arthritis Rheum. 46, 319\u2013329 (2016).","journal-title":"Semin. Arthritis Rheum."},{"key":"25_CR89","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3899\/jrheum.131514","volume":"42","author":"M-A Fitzcharles","year":"2015","unstructured":"Fitzcharles, M.-A. & Jamal, S. Expanding medical marijuana access in Canada: considerations for the rheumatologist. J. Rheumatol. 42, 143\u2013145 (2015).","journal-title":"J. Rheumatol."},{"key":"25_CR90","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.drugpo.2013.08.010","volume":"24","author":"Z Walsh","year":"2013","unstructured":"Walsh, Z. et al. Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use. Int. J. Drug Policy 24, 511\u2013516 (2013).","journal-title":"Int. J. Drug Policy"},{"key":"25_CR91","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1742-1241.2004.00271.x","volume":"59","author":"MA Ware","year":"2005","unstructured":"Ware, M. A., Adams, H., Guy, G. W. & Centre, P. The medicinal use of cannabis in the UK: results of a nationwide survey. Int. J. Clin. Pract. 59, 291\u2013295 (2005).","journal-title":"Int. J. Clin. Pract."},{"key":"25_CR92","doi-asserted-by":"publisher","first-page":"257","DOI":"10.5055\/jom.2009.0028","volume":"5","author":"SK Aggarwal","year":"2009","unstructured":"Aggarwal, S. K. et al. Characteristics of patients with chronic pain accessing treatment with medical cannabis in Washington State. J. Opioid Manag. 5, 257\u2013286 (2009).","journal-title":"J. Opioid Manag."},{"key":"25_CR93","first-page":"CD011694","volume":"7","author":"B Walitt","year":"2016","unstructured":"Walitt, B., Klose, P., Fitzcharles, M. A., Phillips, T. & H\u00e4user, W. Cannabinoids for fibromyalgia. Cochrane Database Syst. Rev. 7, CD011694 (2016).","journal-title":"Cochrane Database Syst. Rev."},{"key":"25_CR94","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jpain.2007.09.002","volume":"9","author":"RQ Skrabek","year":"2008","unstructured":"Skrabek, R. Q., Galimova, L., Ethans, K. & Perry, D. Nabilone for the treatment of pain in fibromyalgia. J. Pain 9, 164\u2013173 (2008).","journal-title":"J. Pain"},{"key":"25_CR95","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1213\/ANE.0b013e3181c76f70","volume":"110","author":"MA Ware","year":"2010","unstructured":"Ware, M. A., Fitzcharles, M.-A., Joseph, L. & Shir, Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth. Analg. 110, 604\u2013610 (2010).","journal-title":"Anesth. Analg."},{"key":"25_CR96","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018440","volume":"6","author":"J Fiz","year":"2011","unstructured":"Fiz, J., Dur\u00e1n, M., Capell\u00e0, D., Carbonell, J. & Farr\u00e9, M. Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. PLoS ONE 6, e18440 (2011).","journal-title":"PLoS ONE"},{"key":"25_CR97","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-15-258","volume":"15","author":"M-A Fitzcharles","year":"2014","unstructured":"Fitzcharles, M.-A. et al. Rheumatologists lack confidence in their knowledge of cannabinoids pertaining to the management of rheumatic complaints. BMC Musculoskelet. Disord. 15, 258 (2014).","journal-title":"BMC Musculoskelet. Disord."},{"key":"25_CR98","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s11481-015-9611-3","volume":"10","author":"RH Robinson","year":"2015","unstructured":"Robinson, R. H. et al. A CB2-selective cannabinoid suppresses T-cell activities and increases Tregs and IL-10. J. Neuroimmune Pharmacol. 10, 318\u2013332 (2015).","journal-title":"J. Neuroimmune Pharmacol."},{"key":"25_CR99","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1136\/annrheumdis-2011-200314","volume":"71","author":"EG Gonzalez","year":"2012","unstructured":"Gonzalez, E. G. et al. Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis. Ann. Rheum. Dis. 71, 1545\u20131551 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"25_CR100","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1001\/jama.2015.6358","volume":"313","author":"PF Whiting","year":"2015","unstructured":"Whiting, P. F. et al. Cannabinoids for medical use. JAMA 313, 2456 (2015).","journal-title":"JAMA"},{"key":"25_CR101","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00482-015-0084-3","volume":"30","author":"M-A Fitzcharles","year":"2016","unstructured":"Fitzcharles, M.-A., Baerwald, C., Ablin, J. & H\u00e4user, W. Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): a systematic review of randomized controlled trials. Schmerz 30, 47\u201361 (2016).","journal-title":"Schmerz"},{"key":"25_CR102","first-page":"71","volume":"19","author":"I Katz","year":"2017","unstructured":"Katz, I., Katz, D., Shoenfeld, Y. & Porat-Katz, B. S. Clinical evidence for utilizing cannabinoids in the elderly. Isr. Med. Assoc. J. 19, 71\u201375 (2017).","journal-title":"Isr. Med. Assoc. J."},{"key":"25_CR103","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009986","volume":"6","author":"JKL Gunn","year":"2016","unstructured":"Gunn, J. K. L. et al. Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. BMJ Open 6, e009986 (2016).","journal-title":"BMJ Open"},{"key":"25_CR104","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/dta.1506","volume":"6","author":"W Hall","year":"2014","unstructured":"Hall, W. & Degenhardt, L. The adverse health effects of chronic cannabis use. Drug Test. Anal. 6, 39\u201345 (2014).","journal-title":"Drug Test. Anal."},{"key":"25_CR105","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3109\/07853890.2016.1145794","volume":"48","author":"RJ Schrot","year":"2016","unstructured":"Schrot, R. J. & Hubbard, J. R. Cannabinoids: medical implications. Ann. Med. 48, 128\u2013141 (2016).","journal-title":"Ann. Med."},{"key":"25_CR106","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/S2215-0366(14)70307-4","volume":"1","author":"E Silins","year":"2014","unstructured":"Silins, E. et al. Young adult sequelae of adolescent cannabis use: an integrative analysis. Lancet Psychiatry 1, 286\u2013293 (2014).","journal-title":"Lancet Psychiatry"},{"key":"25_CR107","first-page":"6353","volume":"22","author":"N Solowij","year":"2016","unstructured":"Solowij, N. Adolescent cannabis use: what is the evidence for functional brain alteration? Curr. Pharm. Des. 22, 6353\u20136365 (2016).","journal-title":"Curr. Pharm. Des."},{"key":"25_CR108","doi-asserted-by":"publisher","first-page":"506.e1","DOI":"10.1016\/j.ajog.2016.05.044","volume":"215","author":"KC Chabarria","year":"2016","unstructured":"Chabarria, K. C. et al. Marijuana use and its effects in pregnancy. Am. J. Obstet Gynecol. 215, 506.e1\u2013506.e7 (2016).","journal-title":"Am. J. Obstet Gynecol."},{"key":"25_CR109","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/mp.2016.252","volume":"23","author":"J Vaucher","year":"2017","unstructured":"Vaucher, J. et al. Cannabis use and risk of schizophrenia: a Mendelian randomization study. Mol. Psychiatry 23, 1287\u20131292 (2017).","journal-title":"Mol. Psychiatry"},{"key":"25_CR110","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1161\/01.CIR.103.23.2805","volume":"103","author":"MA Mittleman","year":"2001","unstructured":"Mittleman, M. A., Lewis, R. A., Maclure, M., Sherwood, J. B. & Muller, J. E. Triggering myocardial infarction by marijuana. Circulation 103, 2805\u20132809 (2001).","journal-title":"Circulation"},{"key":"25_CR111","doi-asserted-by":"publisher","first-page":"6366","DOI":"10.2174\/1381612822666160822151323","volume":"22","author":"A Weinstein","year":"2017","unstructured":"Weinstein, A., Livny, A. & Weizman, A. Brain imaging studies on the cognitive, pharmacological and neurobiological effects of cannabis in humans: evidence from studies of adult users. Curr. Pharm. Des. 22, 6366\u20136379 (2017).","journal-title":"Curr. Pharm. Des."},{"key":"25_CR112","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1002\/art.34522","volume":"64","author":"M-A Fitzcharles","year":"2012","unstructured":"Fitzcharles, M.-A., McDougall, J., Ste-Marie, P. A. & Padjen, I. Clinical implications for cannabinoid use in the rheumatic diseases: potential for help or harm? Arthritis Rheum. 64, 2417\u20132425 (2012).","journal-title":"Arthritis Rheum."},{"key":"25_CR113","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/00004583-199701000-00016","volume":"36","author":"TE Wilens","year":"1997","unstructured":"Wilens, T. E., Biederman, J. & Spencer, T. J. Case study: adverse effects of smoking marijuana while receiving tricyclic antidepressants. J. Am. Acad. Child Adolesc. Psychiatry 36, 45\u201348 (1997).","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"25_CR114","first-page":"280","volume":"52","author":"AL Stoll","year":"1991","unstructured":"Stoll, A. L., Cole, J. O. & Lukas, S. E. A case of mania as a result of fluoxetine-marijuana interaction. J. Clin. Psychiatry 52, 280\u2013281 (1991).","journal-title":"J. Clin. Psychiatry"},{"key":"25_CR115","doi-asserted-by":"publisher","first-page":"bcr2016214806","DOI":"10.1136\/bcr-2016-214806","volume":"2016","author":"A Kokalj","year":"2016","unstructured":"Kokalj, A., Rijavec, N. & Tav\u010dar, R. Delirium with anticholinergic symptoms after a combination of paliperidone and olanzapine pamoate in a patient known to smoke cannabis: an unfortunate coincidence. BMJ Case Rep. 2016, bcr2016214806 (2016).","journal-title":"BMJ Case Rep."},{"key":"25_CR116","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1432-1033.1995.tb20780.x","volume":"232","author":"S Galiegue","year":"1995","unstructured":"Galiegue, S. et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232, 54\u201361 (1995).","journal-title":"Eur. J. Biochem."},{"key":"25_CR117","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0014-5793(95)00746-V","volume":"369","author":"J-M Derocq","year":"1995","unstructured":"Derocq, J.-M., S\u00e9gui, M., Marchand, J., Le Fur, G. & Casellas, P. Cannabinoids enhance human B cell growth at low nanomolar concentrations. FEBS Lett. 369, 177\u2013182 (1995).","journal-title":"FEBS Lett."},{"key":"25_CR118","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/0165-5728(94)90152-X","volume":"55","author":"H Schwarz","year":"1994","unstructured":"Schwarz, H., Blanco, F. J. & Lotz, M. Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J. Neuroimmunol. 55, 107\u2013115 (1994).","journal-title":"J. Neuroimmunol."},{"key":"25_CR119","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0022-3565(24)39301-2","volume":"293","author":"Y Chen","year":"2000","unstructured":"Chen, Y. & Buck, J. Cannabinoids protect cells from oxidative cell death: a receptor-independent mechanism. J. Pharmacol. Exp. Ther. 293, 807\u2013812 (2000).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"25_CR120","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1191\/0960327104ht426oa","volume":"23","author":"M El-Gohary","year":"2004","unstructured":"El-Gohary, M. & Eid, M. A. Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students. Hum. Exp. Toxicol. 23, 149\u2013156 (2004).","journal-title":"Hum. Exp. Toxicol."},{"key":"25_CR121","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.taap.2007.09.012","volume":"226","author":"H-YY Wu","year":"2008","unstructured":"Wu, H.-Y. Y. et al. Cannabidiol-induced apoptosis in primary lymphocytes is associated with oxidative stress-dependent activation of caspase-8. Toxicol. Appl. Pharmacol. 226, 260\u2013270 (2008).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"25_CR122","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.intimp.2007.01.015","volume":"7","author":"T-R Jan","year":"2007","unstructured":"Jan, T.-R., Su, S.-T., Wu, H.-Y. & Liao, M.-H. Suppressive effects of cannabidiol on antigen-specific antibody production and functional activity of splenocytes in ovalbumin-sensitized BALB\/c mice. Int. Immunopharmacol. 7, 773\u2013780 (2007).","journal-title":"Int. Immunopharmacol."},{"key":"25_CR123","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008688","volume":"5","author":"MT Cencioni","year":"2010","unstructured":"Cencioni, M. T. et al. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS ONE 5, e8688 (2010).","journal-title":"PLoS ONE"},{"key":"25_CR124","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.imbio.2009.04.001","volume":"215","author":"SA Rieder","year":"2010","unstructured":"Rieder, S. A., Chauhan, A., Singh, U., Nagarkatti, M. & Nagarkatti, P. Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology 215, 598\u2013605 (2010).","journal-title":"Immunobiology"},{"key":"25_CR125","first-page":"43","volume":"21","author":"S Abo-Elnazar","year":"2014","unstructured":"Abo-Elnazar, S., Moaaz, M., Ghoneim, H., Molokhia, T. & El-Korany, W. Th17\/Treg imbalance in opioids and cannabinoids addiction: relationship to NF-\u03baB activation in CD4 + T cells. Egypt. J. Immunol. 21, 43\u201347 (2014).","journal-title":"Egypt. J. Immunol."},{"key":"25_CR126","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nm1561","volume":"13","author":"K Maresz","year":"2007","unstructured":"Maresz, K. et al. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat. Med. 13, 492\u2013497 (2007).","journal-title":"Nat. Med."},{"key":"25_CR127","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00296-007-0489-0","volume":"28","author":"J Parker","year":"2008","unstructured":"Parker, J. et al. Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid. Rheumatol. Int. 28, 631\u2013635 (2008).","journal-title":"Rheumatol. Int."},{"key":"25_CR128","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/jcb.1103","volume":"81","author":"YH Chang","year":"2001","unstructured":"Chang, Y. H., Lee, S. T. & Lin, W. W. Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids. J. Cell. Biochem. 81, 715\u2013723 (2001).","journal-title":"J. Cell. Biochem."},{"key":"25_CR129","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/sj.bjp.0706215","volume":"145","author":"F Correa","year":"2005","unstructured":"Correa, F., Mestre, L., Docagne, F. & Guaza, C. Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1\/2 kinase signaling. Br. J. Pharmacol. 145, 441\u2013448 (2005).","journal-title":"Br. J. Pharmacol."},{"key":"25_CR130","first-page":"574","volume":"26","author":"E Selvi","year":"2008","unstructured":"Selvi, E. et al. Inhibitory effect of synthetic cannabinoids on cytokine production in rheumatoid fibroblast-like synoviocytes. Clin. Exp. Rheumatol. 26, 574\u2013581 (2008).","journal-title":"Clin. Exp. Rheumatol."},{"key":"25_CR131","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/jcb.21046","volume":"100","author":"DR Johnson","year":"2007","unstructured":"Johnson, D. R., Stebulis, J. A., Rossetti, R. G., Burstein, S. H. & Zurier, R. B. Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid. J. Cell. Biochem. 100, 184\u2013190 (2007).","journal-title":"J. Cell. Biochem."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41584-018-0025-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-018-0025-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-018-0025-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T01:39:30Z","timestamp":1751679570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-018-0025-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,8]]},"references-count":131,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["25"],"URL":"https:\/\/doi.org\/10.1038\/s41584-018-0025-5","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,8]]},"assertion":[{"value":"8 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}